Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

Open access
Krystal, John H., Kavalali, Ege T., Monteggia, Lisa M. · 2024 · Neuropsychopharmacology

Abstract

Ketamine is an open channel blocker of ionotropic glutamatergic N -Methyl- D -Aspartate (NMDA) receptors. The discovery of its rapid antidepressant effects in patients with depression and treatment-resistant depression fostered novel effective treatments for mood disorders. This discovery not only provided new insight into the neurobiology of mood disorders but also uncovered fundamental synaptic plasticity mechanisms that underlie its treatment. In this review, we discuss key clinical aspects of ketamine’s effect as a rapidly acting antidepressant, synaptic and circuit mechanisms underlying its action, as well as how these novel perspectives in clinical practice and synapse biology form a road map for future studies aimed at more effective treatments for neuropsychiatric disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-023-01629-w

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Converging synaptic signaling pathways underlying ketamine action. The figure depicts a basic synaptic circuit where an excitatory pyramidal neuron receives inputs from other excitatory neurons as well as inhibitory neurons. At excitatory glutamatergic synapses onto excitatory neurons, glutamate release and NMDA receptor activation leads to activation of eEF2 kinase, triggering eEF2 phosphorylation and silencing of brain-derived neurotrophic factor (BDNF) translation. Ketamine-mediated NMDA receptor blockade, in turn, ceases tonic eEF2 kinase activity, resulting in a gradual loss of eEF2 phosphorylation and de-suppression of BDNF translation, ultimately triggering TrkB receptor signaling. TrkB signaling and subsequent rapid homeostatic synaptic plasticity is required to elicit not only rapid effects of ketamine but also its sustained effects. In the meantime, ketamine-mediated transient reduction of excitatory drive onto inhibitory interneuron resident NMDARs is postulated to suppress tonic release of GABA and disinhibit activity of the target excitatory neurons. The resulting increase in glutamatergic activity produces downstream activation of mammalian target of rapamycin (mTOR) function to elicit structural plasticity and produce the rapid and sustained antidepressant effects. While the two pathways may act synergistically, it is important to note that mTOR may also acts as a downstream target for TrkB signaling, which may be a point of convergence of the two pathways. These initial synaptic plasticity events trigger sustained effects of ketamine via transcriptional processes. This figure was made by BioRender.
Fig. 1 Converging synaptic signaling pathways underlying ketamine action. The figure depicts a basic synaptic circuit where an excitatory pyramidal neuron receives inputs from other excitatory neurons as well as inhibitory neurons. At excitatory glutamatergic synapses onto excitatory neurons, glutamate release and NMDA receptor activation leads to activation of eEF2 kinase, triggering eEF2 phosphorylation and silencing of brain-derived neurotrophic factor (BDNF) translation. Ketamine-mediated NMDA receptor blockade, in turn, ceases tonic eEF2 kinase activity, resulting in a gradual loss of eEF2 phosphorylation and de-suppression of BDNF translation, ultimately triggering TrkB receptor signaling. TrkB signaling and subsequent rapid homeostatic synaptic plasticity is required to elicit not only rapid effects of ketamine but also its sustained effects. In the meantime, ketamine-mediated transient reduction of excitatory drive onto inhibitory interneuron resident NMDARs is postulated to suppress tonic release of GABA and disinhibit activity of the target excitatory neurons. The resulting increase in glutamatergic activity produces downstream activation of mammalian target of rapamycin (mTOR) function to elicit structural plasticity and produce the rapid and sustained antidepressant effects. While the two pathways may act synergistically, it is important to note that mTOR may also acts as a downstream target for TrkB signaling, which may be a point of convergence of the two pathways. These initial synaptic plasticity events trigger sustained effects of ketamine via transcriptional processes. This figure was made by BioRender.CC BY · PubMed Central
Fig. 2 Role of presynaptic disinhibition of glutamate release in ketamine action. The figure depicts an alternative basic synaptic circuit where an excitatory pyramidal neuron receives inputs from other excitatory neurons, where inhibitory inputs regulate the extent of glutamate release from primary excitatory neurons. While this circuit is not mutually exclusive with the one presented in Fig. 1, it highlights the role of NMDA receptors on inhibitory neurons and their impact on regulation of glutamate release. According to this “disinhibition” model, ketamine predominantly acts on inhibitory interneurons, curtailing their tonic NMDAR dependent activity and in turn augmenting excitability of glutamatergic neurons as well as ensuing glutamate release. This increased glutamate release activates postsynaptic AMPA receptors leading to activation of mTOR signaling. This figure was made by BioRender.
Fig. 2 Role of presynaptic disinhibition of glutamate release in ketamine action. The figure depicts an alternative basic synaptic circuit where an excitatory pyramidal neuron receives inputs from other excitatory neurons, where inhibitory inputs regulate the extent of glutamate release from primary excitatory neurons. While this circuit is not mutually exclusive with the one presented in Fig. 1, it highlights the role of NMDA receptors on inhibitory neurons and their impact on regulation of glutamate release. According to this “disinhibition” model, ketamine predominantly acts on inhibitory interneurons, curtailing their tonic NMDAR dependent activity and in turn augmenting excitability of glutamatergic neurons as well as ensuing glutamate release. This increased glutamate release activates postsynaptic AMPA receptors leading to activation of mTOR signaling. This figure was made by BioRender.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 132 references

Research works printed but not linked: 2

  1. Kuhn R. The discovery of the tricyclic antidepressants and the history of their use in the early years. In: Ban TA, Ray OS, editors. A History of the CINP. Brentwood: Brentwood press; 1996. p. 425–35.
  2. Berman RM, Krystal JH, Charney DS. Mechanism of action of antidepressants: monoamine hypotheses and beyond. In: Watson SJ, editor. Biology of Schizophrenia and Affective Disorders. Washington, D.C.: American psychiatric press, Inc; 1996. p. 295–368.

Cited by

See all 277

Metadata

Authors
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M.
Affiliations
  • Yale University (US)
  • Vanderbilt University (US)
Corresponding author
Monteggia, Lisa M.
Venue
Neuropsychopharmacology
Published
2023-07-24
Volume
49
Issue
1
Pages
41-50
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4385196900
Cited by
262
References
132
Citations by year
2026: 99 · 2025: 98 · 2024: 60 · 2023: 5
FWCI
9.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH070727, MH081060, MH066198)
  • Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs (National Center for PTSD)
  • Yale | YSM | Yale Center for Clinical Investigation, Yale School of Medicine (2UL1TR001863)
  • U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (2P50AA012870)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, treatment-resistant depression, NMDA receptor antagonism, synaptic plasticity, synaptic signaling, mood disorders, neuropsychiatric disorders, antidepressant mechanism
MeSH terms
Antidepressive Agents, Depression, Humans, Ketamine, Synapses, Receptors, N-Methyl-D-Aspartate, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. https://app.cochat.ai/papers/10.1038/s41386-023-01629-w
The paper
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01629-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.